Dofetilide
Authors:
- 21 November 2000
- journal article
- review article
- Published by Wolters Kluwer Health in Circulation
- Vol. 102 (21) , 2665-2670
Abstract
Dofetilide is a new antiarrhythmic drug that recently was recommended for approval by an advisory committee to the Food and Drug Administration (FDA) for treatment of patients with persistent atrial fibrillation. Dofetilide is a specific blocker of the rapid component of the outward delayed rectifier potassium current I Kr and will represent the first drug with relatively pure class III antiarrhythmic properties to be widely released. Cardiac depolarization results principally from the flow of inward Na+ and Ca2+ ions as the rapid and slow inward currents. Repolarization results from a balance between inactivation of the slow inward current and activation of repolarizing predominantly K+ currents. Early repolarization results from a transient outward current, I TO, which is activated rapidly by membrane depolarization. Terminal repolarization is mediated by outward delayed rectifier K+ currents, I K, which are activated slowly (over a period of 200 to 300 ms) on membrane depolarization and turn off, or deactivate, relatively slowly on membrane repolarization. I K can be separated pharmacologically into 2 components: a rapidly activating component, I Kr, and a slower component, I Ks, each carried by a separate ion channel molecule.1 2 HERG channels are responsible for I Kr, whereas I Ks flows through KvLQT1 channels. Specific blockers of I Kr are therefore classified as pure class III antiarrhythmic agents because they produce only prolongation of action potential duration (and hence of QT interval). These actions may result in arrhythmia termination or suppression but can also lead to excess QT prolongation and polymorphic ventricular tachycardia. Examples of specific I Kr blockers include the methanesulfonanilide agents dofetilide, E4031, almokalant, and d-sotalol. ### Effects of Dofetilide on I kr Dofetilide blocks I Kr in all myocardial tissues with high potency (50% effective concentration [EC50] in the nanomolar range). Block …Keywords
This publication has 51 references indexed in Scilit:
- Dofetilide in Patients with Congestive Heart Failure and Left Ventricular DysfunctionNew England Journal of Medicine, 1999
- Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: A multicenter, randomized, double-blind, placebo-controlled trialAmerican Heart Journal, 1999
- Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: Rationale, design, and patient characteristics of the DIAMOND studiesClinical Cardiology, 1997
- Efficacy and safety of dofetilide, a new class III antiarrhythmic agent, in acute termination of atrial fibrillation or flutter after coronary artery bypass surgeryInternational Journal of Cardiology, 1997
- Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardiaThe American Journal of Cardiology, 1995
- Frequency-dependent effects of E-4031, almokalant, dofetilide and tedisamil on action potential duration: no evidence for “reverse use dependent” blockNaunyn-Schmiedeberg's Archives of Pharmacology, 1994
- Electrophysiological and inotropic effects of H 234/09 (almokalant) in vitro: a comparison with two other novel IK blocking drugs, UK-68,798 (dofetilide) and E-4031Cardiovascular Research, 1993
- Effects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectorisThe American Journal of Cardiology, 1992
- Clinical and electrophysiologic effects of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with angina pectorisThe American Journal of Cardiology, 1992
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976